Xofluza 40 mg, Filmtabletten - 2 Swissmedic Key 67426004 Registration Holder Roche Pharma (Schweiz) AG Name Xofluza 40 mg, Filmtabletten Date of registration 19.02.2020 Introduction of Sequence 19.02.2020 ATC-Classification Baloxavir Marboxil (J05AX25) Revision date WHO WHO-DDD Valid until Index Therapeuticus (BSV) Show package size 2 Index Therapeuticus (Swissmedic) 08.03. Description Swissmedic categorie. B SL Eintrag No Indication Information for professionals IP Consumer information Ex-factory-Price PR Deductible k.A. Consumer price PR Feedback FB GTIN 7680674260042 Medication Code Synthetika Pharmacode Disponibility
Composition baloxavirum marboxilum 40 mg, lactosum monohydricum 155.8 mg, carmellosum natricum conexum, povidonum K 25, cellulosum microcristallinum, natrii stearylis fumaras, talcum, Überzug: hypromellosum, talcum, E 171, pro compresso obducto corresp. natrium 2.26 mg. Packungsbestandteile Galenic Form Coated tablets Active Agent Dose Baloxavirum Marboxilum 40 mg
Inactive agents Dose additional_information Carmellosum Natricum Conexum Cellulosum Microcristallinum E 171 color. Hypromellosum Überzug Lactose Monohydrate 155.8 mg Natrii Stearylis Fumaras Povidonum K 25 Pro Compresso Obducto Talcum
Source Data was imported : 05.09.2024
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
